-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 16, 2022, Equillium announced the acquisition of Bioniz Therapeutics
Through this acquisition, Equillium's immunology R&D pipeline and technology platform include:
BNZ-1: A potential "first-in-class" trispecific inhibitor that inhibits the inflammatory cytokines interleukin (IL)-2, IL-9 and IL-15 associated with various diseases
BNZ-2: a potential "first-in-class" selective inhibitor of IL-15 and IL-21
Discovery Platform: Bioniz's flexible, structure-based technology platform combined with deep insights into cytokine pathways and computational modeling creates discovery capabilities that result in highly differentiated immunology products
▲Bioniz product pipeline (picture source: Bioniz official website)
References:
[1] Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates.
(Original abridged)